Review



anti il12 antibody  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Miltenyi Biotec anti il12 antibody
    Anti Il12 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 36 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il12/IL-4+Antibody%2C+anti-human/pm42288905-219-37-39
    Average 94 stars, based on 36 article reviews
    anti il12 antibody - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    other:

    Article Title: NEDDylation Regulates CD8 + T-cell Metabolism and Antitumor Immunity
    Article Snippet: Cells were activated at 1 × 10 6 cells/mL using anti-CD3 and anti-CD28 Dynabeads in a 1:1 ratio, in RPMI 1640 Glutamax medium supplemented with 10% FBS, 1% penicillin–streptomycin, 25 ng/mL IL2, and 10 ng/mL IL12 (Miltenyi Biotech, cat. #: 130-096-708).

    Suspension:

    Article Title: Single-Cell Profiling Reveals Functional Heterogeneity and Serial Killing in Human Peripheral and Ex Vivo-Generated CD34+ Progenitor-Derived Natural Killer Cells.
    Article Snippet: The cells were then resuspended in NK MACS medium (Miltenyi, Catalog no. 130-107-209) supplemented with 10% HS and 1% NK MACS supplement (Miltenyi) at the concentration of 3 million cells mL−1. .. The cells suspension (1.5 mL) was loaded into the 6 well plates and supplemented by IL15 (Immunotools, Catalog no. 352 310; 50 ng mL−1) and IL12 (Miltenyi, Catalog no. 130-096-704; 0.2 ng mL−1). ..

    Article Title: Single cell profiling reveals functional heterogeneity and serial killing in human peripheral and ex vivo-generated CD34+ progenitor derived Natural Killer cells
    Article Snippet: The cells were then resuspended in NK MACS medium (Miltenyi, Catalog no. 130-107-209) supplemented with 10% HS and 1% NK MACS supplement (Miltenyi) at the concentration of 3 million cells/mL. .. 1.5 mL of the cell suspension was loaded into the 6 well plate and were supplemented by 50 ng/mL IL15 (Immunotools, Catalog no. 352310) and 0.2 ng/mL IL12 (Miltenyi, Catalog no. 130-096-704). ..



    Similar Products

    anti il12 antibody  (Miltenyi Biotec)
    94
    Miltenyi Biotec anti il12 antibody
    Anti Il12 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il12/IL-4+Antibody%2C+anti-human/pm42288905-219-37-39
    Average 94 stars, based on 1 article reviews
    anti il12 antibody - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    hek blue reporter assay il12  (InvivoGen)
    95
    InvivoGen hek blue reporter assay il12
    Hek Blue Reporter Assay Il12, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il12/HEK-Blue+IL-12+Cells/pm41944084-322-17-23
    Average 95 stars, based on 1 article reviews
    hek blue reporter assay il12 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    hek-blue il-12 cells  (InvivoGen)
    95
    InvivoGen hek-blue il-12 cells
    Hek Blue Il 12 Cells, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il12/HEK-Blue+IL-12+Cells/custom%40hkb-il12%4010%2E64898%2F2026%2E09%2E07%2E749923
    Average 95 stars, based on 1 article reviews
    hek-blue il-12 cells - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    il12 results  (Exosome Diagnostics)
    86
    Exosome Diagnostics il12 results
    Il12 Results, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il12/display+exosome+surface+technology/pm42321851-3043-18-14
    Average 86 stars, based on 1 article reviews
    il12 results - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    hek blue il 12  (InvivoGen)
    95
    InvivoGen hek blue il 12
    A , A panel of dimeric (Fc) and monomeric (MSA) cytokine fusions to untargeted, collagen-anchored, or HA-anchored proteins was engineered. B , Mice bearing B16F10 or MC38 tumors were treated days 6 and day 13 after tumor induction with 0.11 nmol IL-15 and 0.014 nmol <t>IL-12.</t> Mice were monitored for tumor burden and weight loss. C , Kaplan-Meier survival and ( D ) weight loss of mice bearing B16F10 tumors intratumorally injected with PBS or cytokine fusion proteins (mean ± SD, n = 11). E , Kaplan-Meier survival and ( F ) weight loss of mice bearing MC38 tumors treated with PBS or cytokine fusions (mean ± SD, n = 5). Statistics: analysis of survival was performed using log-rank Mantel-Cox test. Weights compared by two-way ANOVA with Tukey’s multiple comparison test. ns, not significant; ****P < 0.0001.
    Hek Blue Il 12, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il12/HEK-Blue+IL-12+Cells/bio_rxiv__64898__2026__04__06__716711-126-6-8
    Average 95 stars, based on 1 article reviews
    hek blue il 12 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    cynomolgus il12  (R&D Systems)
    94
    R&D Systems cynomolgus il12
    SDC demonstrates dual functionality. (A) Neutralization of TNF-α-mediated cytotoxicity in mouse fibrosarcoma L929 cells. (B,C) Neutralization of human IL-23-induced Tyk2-JAK2 heterodimerization and STAT3 phosphorylation in HEK-Blue IL-23 Reporter Cell. HEK-Blue IL-23 cells were treated with recombinant human IL-23 (1 ng/mL) and dilution series of (B) tofacitinib and (C) ELN28-135-01 with and without HNE (50 nM). (D) Neutralization of <t>cynomolgus</t> <t>IL-12-induced</t> Tyk2-JAK2 heterodimerization and STAT4 phosphorylation in the HEK-Blue IL-12 Reporter Cell. Data are shown as mean ± SEM ( n = 2). (E) Inhibition of PHA-mediated proliferation of human PBMC samples. Human PBMCs were stimulated with PHA and treated with either tofacitinib, ELN28-135-01 in the presence or absence of HNE, ELN22-135, or ELN0-2V-135-01 in the presence or absence of HNE. (F) Inhibition of PHA-mediated proliferation of PBMCs from 4 additional donors. Human PBMCs were stimulated with PHA and treated with either tofacitinib or ELN28-135-01 in the presence of HNE. Data are shown as mean ± SEM ( n = 2), ND 50 values were calculated using four-parameter nonlinear regression.
    Cynomolgus Il12, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il12/Recombinant+Cynomolgus+Monkey+IL-12+(linked+heterodimer)%2C+CF/pmc13126671-306-31-34
    Average 94 stars, based on 1 article reviews
    cynomolgus il12 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    A , A panel of dimeric (Fc) and monomeric (MSA) cytokine fusions to untargeted, collagen-anchored, or HA-anchored proteins was engineered. B , Mice bearing B16F10 or MC38 tumors were treated days 6 and day 13 after tumor induction with 0.11 nmol IL-15 and 0.014 nmol IL-12. Mice were monitored for tumor burden and weight loss. C , Kaplan-Meier survival and ( D ) weight loss of mice bearing B16F10 tumors intratumorally injected with PBS or cytokine fusion proteins (mean ± SD, n = 11). E , Kaplan-Meier survival and ( F ) weight loss of mice bearing MC38 tumors treated with PBS or cytokine fusions (mean ± SD, n = 5). Statistics: analysis of survival was performed using log-rank Mantel-Cox test. Weights compared by two-way ANOVA with Tukey’s multiple comparison test. ns, not significant; ****P < 0.0001.

    Journal: bioRxiv

    Article Title: Engineering hyaluronic acid-binding cytokines for enhanced tumor retention and safety

    doi: 10.64898/2026.04.06.716711

    Figure Lengend Snippet: A , A panel of dimeric (Fc) and monomeric (MSA) cytokine fusions to untargeted, collagen-anchored, or HA-anchored proteins was engineered. B , Mice bearing B16F10 or MC38 tumors were treated days 6 and day 13 after tumor induction with 0.11 nmol IL-15 and 0.014 nmol IL-12. Mice were monitored for tumor burden and weight loss. C , Kaplan-Meier survival and ( D ) weight loss of mice bearing B16F10 tumors intratumorally injected with PBS or cytokine fusion proteins (mean ± SD, n = 11). E , Kaplan-Meier survival and ( F ) weight loss of mice bearing MC38 tumors treated with PBS or cytokine fusions (mean ± SD, n = 5). Statistics: analysis of survival was performed using log-rank Mantel-Cox test. Weights compared by two-way ANOVA with Tukey’s multiple comparison test. ns, not significant; ****P < 0.0001.

    Article Snippet: B16F10 (ATCC), MC38 (ATCC), Expi293F (Gibco), HEK-Blue IL-12 (Invivogen), and CTLL-2 (ATCC) cells were cultured following vendor instructions.

    Techniques: Injection, Comparison

    A , B16F10- or MC38-tumor bearing mice were intratumorally injected with 0.22 nmol IL-15 and 0.028 nmol IL-12 fusion proteins 6 days after tumor induction. Weight loss was monitored for 5 days post-treatment (mean ± SD, n =5). Percent weight change measured from the start of treatment in B16F10 ( B ) and MC38 ( C ) tumor-bearing mice. D , Mice were treated as described above, and blood collected 1 and 3 days post-treatment for analysis of ALT activity and serum cytokine/chemokine levels (mean ± SD, n =5). E , Alanine aminotransferase activity in serum 1 and 3 days post-treatment. F , Z-scored expression of serum cytokines and chemokines for each cohort 1 and 3 days post-treatment. G-I, Serum concentrations of ( G ) IFNɣ, ( H ) IFNɑ, and ( I ) TNFɑ tested at both timepoints. J , B16F10 tumor-bearing mice were treated with 0.11 nmol IL-15 and 0.014 nmol IL-12 of indicated cytokine fusions 6 days post-tumor inoculation. Mice were injected both intratumorally and on their healthy contralateral flank. Seven days after the primary injection, mice were either euthanized for tissue collection or treated again. Six days after the second injection, the rest of the mice were euthanized for histopathological analysis of tissues (n=6). K , (Left) Macroscopic images of dosed contralateral flank after 2 cytokine injections. (Center, right) H&E stained skin sections of contralateral flank after 1 (center) or 2 (right) subcutaneous injections of cytokine fusions. Statistics: two-way ANOVA with Tukey’s multiple comparison test. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Journal: bioRxiv

    Article Title: Engineering hyaluronic acid-binding cytokines for enhanced tumor retention and safety

    doi: 10.64898/2026.04.06.716711

    Figure Lengend Snippet: A , B16F10- or MC38-tumor bearing mice were intratumorally injected with 0.22 nmol IL-15 and 0.028 nmol IL-12 fusion proteins 6 days after tumor induction. Weight loss was monitored for 5 days post-treatment (mean ± SD, n =5). Percent weight change measured from the start of treatment in B16F10 ( B ) and MC38 ( C ) tumor-bearing mice. D , Mice were treated as described above, and blood collected 1 and 3 days post-treatment for analysis of ALT activity and serum cytokine/chemokine levels (mean ± SD, n =5). E , Alanine aminotransferase activity in serum 1 and 3 days post-treatment. F , Z-scored expression of serum cytokines and chemokines for each cohort 1 and 3 days post-treatment. G-I, Serum concentrations of ( G ) IFNɣ, ( H ) IFNɑ, and ( I ) TNFɑ tested at both timepoints. J , B16F10 tumor-bearing mice were treated with 0.11 nmol IL-15 and 0.014 nmol IL-12 of indicated cytokine fusions 6 days post-tumor inoculation. Mice were injected both intratumorally and on their healthy contralateral flank. Seven days after the primary injection, mice were either euthanized for tissue collection or treated again. Six days after the second injection, the rest of the mice were euthanized for histopathological analysis of tissues (n=6). K , (Left) Macroscopic images of dosed contralateral flank after 2 cytokine injections. (Center, right) H&E stained skin sections of contralateral flank after 1 (center) or 2 (right) subcutaneous injections of cytokine fusions. Statistics: two-way ANOVA with Tukey’s multiple comparison test. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Article Snippet: B16F10 (ATCC), MC38 (ATCC), Expi293F (Gibco), HEK-Blue IL-12 (Invivogen), and CTLL-2 (ATCC) cells were cultured following vendor instructions.

    Techniques: Injection, Activity Assay, Expressing, Staining, Comparison

    A , B16F10 tumor-bearing mice were intratumorally injected with 0.05 nmol of indicated IL-12 fusion proteins 8 days after tumor inoculation. Mice were euthanized and tumors collected 5 days later for downstream flow cytometric analysis (mean ± SD, n=5). B, Treatment effects on proportion and ( C ) count of tumor-infiltrating CD45+ leukocytes. D , Representative histograms and gating for pSTAT4+ cells, previously gated on CD45+ cells. E , Proportion and ( F ) count of pSTAT4+ cells in the whole CD45+ compartment. G , Treatment effects on proportion and ( H ) count of tumor-infiltrating T cells. I , Representative histograms and gating of pSTAT4+ cells in the CD3+ compartment. J , Proportion and ( K ) count of pSTAT4+ T cells in the tumor. Statistics: one-way ANOVA followed by Tukey’s multiple-comparison test. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Journal: bioRxiv

    Article Title: Engineering hyaluronic acid-binding cytokines for enhanced tumor retention and safety

    doi: 10.64898/2026.04.06.716711

    Figure Lengend Snippet: A , B16F10 tumor-bearing mice were intratumorally injected with 0.05 nmol of indicated IL-12 fusion proteins 8 days after tumor inoculation. Mice were euthanized and tumors collected 5 days later for downstream flow cytometric analysis (mean ± SD, n=5). B, Treatment effects on proportion and ( C ) count of tumor-infiltrating CD45+ leukocytes. D , Representative histograms and gating for pSTAT4+ cells, previously gated on CD45+ cells. E , Proportion and ( F ) count of pSTAT4+ cells in the whole CD45+ compartment. G , Treatment effects on proportion and ( H ) count of tumor-infiltrating T cells. I , Representative histograms and gating of pSTAT4+ cells in the CD3+ compartment. J , Proportion and ( K ) count of pSTAT4+ T cells in the tumor. Statistics: one-way ANOVA followed by Tukey’s multiple-comparison test. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

    Article Snippet: B16F10 (ATCC), MC38 (ATCC), Expi293F (Gibco), HEK-Blue IL-12 (Invivogen), and CTLL-2 (ATCC) cells were cultured following vendor instructions.

    Techniques: Injection, Comparison

    SDC demonstrates dual functionality. (A) Neutralization of TNF-α-mediated cytotoxicity in mouse fibrosarcoma L929 cells. (B,C) Neutralization of human IL-23-induced Tyk2-JAK2 heterodimerization and STAT3 phosphorylation in HEK-Blue IL-23 Reporter Cell. HEK-Blue IL-23 cells were treated with recombinant human IL-23 (1 ng/mL) and dilution series of (B) tofacitinib and (C) ELN28-135-01 with and without HNE (50 nM). (D) Neutralization of cynomolgus IL-12-induced Tyk2-JAK2 heterodimerization and STAT4 phosphorylation in the HEK-Blue IL-12 Reporter Cell. Data are shown as mean ± SEM ( n = 2). (E) Inhibition of PHA-mediated proliferation of human PBMC samples. Human PBMCs were stimulated with PHA and treated with either tofacitinib, ELN28-135-01 in the presence or absence of HNE, ELN22-135, or ELN0-2V-135-01 in the presence or absence of HNE. (F) Inhibition of PHA-mediated proliferation of PBMCs from 4 additional donors. Human PBMCs were stimulated with PHA and treated with either tofacitinib or ELN28-135-01 in the presence of HNE. Data are shown as mean ± SEM ( n = 2), ND 50 values were calculated using four-parameter nonlinear regression.

    Journal: Journal of Medicinal Chemistry

    Article Title: A Rationally Designed Novel Bifunctional Human TNF-α- and Janus Kinase-Targeted soloMER Drug Conjugate (SDC) with a Neutrophil Elastase Cleavable Linker Delivering Inflammation Site-Specific Release of Payload

    doi: 10.1021/acs.jmedchem.6c00532

    Figure Lengend Snippet: SDC demonstrates dual functionality. (A) Neutralization of TNF-α-mediated cytotoxicity in mouse fibrosarcoma L929 cells. (B,C) Neutralization of human IL-23-induced Tyk2-JAK2 heterodimerization and STAT3 phosphorylation in HEK-Blue IL-23 Reporter Cell. HEK-Blue IL-23 cells were treated with recombinant human IL-23 (1 ng/mL) and dilution series of (B) tofacitinib and (C) ELN28-135-01 with and without HNE (50 nM). (D) Neutralization of cynomolgus IL-12-induced Tyk2-JAK2 heterodimerization and STAT4 phosphorylation in the HEK-Blue IL-12 Reporter Cell. Data are shown as mean ± SEM ( n = 2). (E) Inhibition of PHA-mediated proliferation of human PBMC samples. Human PBMCs were stimulated with PHA and treated with either tofacitinib, ELN28-135-01 in the presence or absence of HNE, ELN22-135, or ELN0-2V-135-01 in the presence or absence of HNE. (F) Inhibition of PHA-mediated proliferation of PBMCs from 4 additional donors. Human PBMCs were stimulated with PHA and treated with either tofacitinib or ELN28-135-01 in the presence of HNE. Data are shown as mean ± SEM ( n = 2), ND 50 values were calculated using four-parameter nonlinear regression.

    Article Snippet: Actinomycin D (1229, R&D Systems), Healthy human PBMCs (Precision Medicine), HEK Blue Reporter Assay IL23 (hkb-il23, InvivoGen), HEK Blue Reporter Assay IL12 (hkb-il12, InvivoGen), L929 (Sigma), human IL23 (1290-IL/CF, R&D Systems), cynomolgus IL12 (10215-CL, R&D systems), human neutrophil elastase (324681, Merck), human TNF-α (TNFA-HA4211, Acro Bioscience), Phytohemagglutinin-L (PHA) (11249738001, Sigma), QUANTI-Blue solution (rep-qbs, InvivoGen), tofacitinib (FT32555, Biosynth), WST-1 reagent (11644807001, Merck), mIL-6 (Quantikine ELISA, M6000B, R&D Systems), MCP-1 (Quantikine ELISA, JE00B, R&D Systems), and CXCL1 (DuoSet ELISA, DY453, R&D Systems).

    Techniques: Neutralization, Phospho-proteomics, Recombinant, Inhibition